Association between serum 25(OH) vitamin D and the risk of cognitive decline in older women

Yelena Slinin, Misti Paudel, Brent C Taylor, Areef Ishani, Rebecca Rossom, Kristine Yaffe, Terri Blackwell, Li-Yung Lui, Marc Hochberg, Kristine E Ensrud, Study of Osteoporotic Fractures Research Group, Yelena Slinin, Misti Paudel, Brent C Taylor, Areef Ishani, Rebecca Rossom, Kristine Yaffe, Terri Blackwell, Li-Yung Lui, Marc Hochberg, Kristine E Ensrud, Study of Osteoporotic Fractures Research Group

Abstract

Background: Results of prospective studies examining the association between 25 hydroxyvitamin D (25[OH]D) levels and cognitive decline have been inconsistent. We tested the hypothesis that lower 25(OH)D levels are associated with a greater likelihood of cognitive impairment and risk of cognitive decline.

Methods: The study is a cross-sectional and longitudinal analysis of a prospective cohort of 6,257 community-dwelling elderly women followed for 4 years. Global cognitive function was measured by the Modified Mini-Mental State Examination and executive function was measured by Trail Making Test Part B (Trails B). Cognitive impairment at baseline was defined as a score >1.5 SD below the sample mean; cognitive decline was defined as decline from baseline to follow-up >1 SD from mean change in score.

Results: Women with very low vitamin D levels had an increased odds of global cognitive impairment at baseline: odds ratio (95% confidence interval), 1.60 (1.05-2.42) for women with 25(OH)D <10 ng/mL (25 nmol/L) compared with those with 25(OH)D levels ≥30 ng/mL (75 nmol/L). Compared with women with baseline 25(OH)D level ≥30 ng/mL (75 nmol/L), women with lower levels had an increased risk of global cognitive decline: odds ratio (95% confidence interval), 1.58(1.12-2.22) for women with levels <10 ng/mL (25 nmol/L), and 1.31 (1.04-1.64) for those with levels 10-19.9 ng/mL (25-49 nmol/L). Levels of 25(OH)D were not associated with executive cognitive function.

Conclusions: Low 25(OH)D levels among older women were associated with a higher odds of global cognitive impairment and a higher risk of global cognitive decline.

Figures

Figure 1.
Figure 1.
Study roadmap.
Figure 2.
Figure 2.
Change in cognitive function by category of serum 25(OH)D concentration. Results are based on a random-effects model with multivariate adjustment for clinic site, season of blood collection, age at baseline, years of education, self-reported health status, instrumental activity of daily living impairments, smoking status at baseline, body mass index, history of hypertension, history of diabetes, depression, and baseline cognitive score. P values for comparison with >30ng/mL (reference): 20–29 ng/mL p= .1630; 10–19 ng/mL p = .7969; <10 ng/mLp = .0385.

Source: PubMed

3
Abonneren